Mass Tort Financing Explained: Costs, Lenders, Cash Flow
Summary Mass tort financing is the capital plaintiff firms use to acquire cases, run lead generation, and cover operating costs during the years-long wait between client signup and settlement. This post breaks down the three main structures (case acquisition financing, marketing capital, and working capital lines), who lends, what it actually costs, and the cash flow math you should run before signing. Read this first if you're considering a mass tort buildup.
A single mass tort claimant can cost anywhere from a few hundred to several thousand dollars to acquire. A firm signing 1,000 hair relaxer or Camp Lejeune claimants is staring at multimillion-dollar marketing and intake bills years before the cases monetize. That's the math problem mass tort financing exists to solve.
It's also the math problem that puts firms out of business when the financing is wrong.
Mass tort financing isn't a single product. It's a category that covers case acquisition financing, marketing capital, and working capital lines collateralized by case inventory. Each one has different lenders, different pricing, and different risks. We see plaintiff firms borrow into a mass tort buildup without modeling the cash flow trough, then run out of operating cash 18 months in.
This post walks through what mass tort financing actually is, who provides it, what it costs, and how to think about the borrowing decision from a CPA's perspective.
What Is Mass Tort Financing?
Mass tort financing is specialty capital plaintiff firms use to fund case acquisition, marketing, and operating costs during the multi-year wait between signing claimants and settlement. It's a sub-market of litigation finance built for firms running large mass tort or MDL inventories. The capital is usually secured by the firm's pending case inventory rather than personal guarantees alone.
The category covers three product types:
- Case acquisition financing. Capital advanced specifically to fund client signups: signup fees, doc retrieval, qualification screening, and intake.
- Marketing capital. A working capital line tied to lead generation spend, with reporting requirements on cost-per-lead and intake-to-retain ratios.
- Working capital and inventory lines. Revolving capital secured by the firm's pending case inventory to fund payroll, rent, and ongoing case prosecution.
Most firms running a serious mass tort campaign use some combination of all three.
Why Mass Tort Cases Are Different to Fund
Mass tort economics don't look like a normal contingency practice. Three factors drive the difference.
Long timelines. Multidistrict litigation cases routinely run several years from formation to global resolution, and the Judicial Panel on Multidistrict Litigation publishes pendency statistics showing some of the largest dockets stretching past a decade. A firm signing claimants today should plan on a 3 to 7-year hold before the bulk of fees come in.
High acquisition cost. Mass tort marketing is one of the most expensive verticals in legal advertising. Industry trackers regularly report billions of dollars in legal services TV advertising each year, with a large share aimed at mass tort campaigns. Cost-per-lead can run from under $100 to several thousand dollars depending on the docket and the channel.
Attrition. Not every signed claimant becomes a qualified, paid claimant. Plaintiff firms typically see meaningful attrition between intake and final qualification, which means the realized case acquisition cost per paid claimant is higher than the headline number.
Layer those three together and you get a working capital problem that's structurally different from an hourly defense or transactional practice.
How Does Case Acquisition Financing Work?
Case acquisition financing is capital advanced on a per-claimant basis (or against a pool of expected signups) to fund the direct cost of intake. Lenders advance against a target case acquisition cost per claimant, with controls on lead source quality and intake reporting. Repayment comes out of settlement proceeds, often before the firm sees its net.
In practice, the structure looks something like this: a lender commits a facility (say $5 million), the firm draws against it as it signs claimants in approved campaigns, and the lender takes a senior position against the proceeds when cases settle. Some advances are non-recourse to the firm, secured only by the cases. Others are recourse, with personal or firm guarantees layered on.
The underwriting question lenders ask is the same one a CFO would: what's the modeled net per case after fees, liens, co-counsel splits, and the financing itself? If that number doesn't work, no amount of marketing solves the problem. This is also why managing advanced client costs cleanly is non-negotiable. Lenders want to see a per-case ledger, not a lump sum.
What Is Marketing Capital in a Mass Tort Build?
Marketing capital is a working capital line dedicated to lead generation spend: TV, digital, search, social, and lead-gen vendor fees. Unlike case acquisition financing (which advances against signed claimants), marketing capital funds the ad spend that drives the leads in the first place. Lenders in this category require detailed reporting on cost-per-lead, intake-to-retain ratios, and lead source quality.
The reason marketing capital exists as a separate product: ad spend is front-loaded in a campaign, but the cases it generates take years to monetize. A firm running a full-funnel mass tort program may spend several million dollars in a 90-day window to capture market share on a new docket. Without dedicated marketing capital, that spend has to come out of operating cash, which most plaintiff firms don't have.
In our work with plaintiff firms, we see the difference between firms that treat marketing capital as a strategic investment, with clear payback modeling, and firms that treat it as an emergency credit line. The first group tends to grow profitably. The second group refinances every 18 months at progressively worse terms.
Working Capital and Inventory-Backed Lines
A working capital line for a mass tort firm is usually structured as a revolving facility secured by the firm's pending case inventory. The lender assigns a borrowing base (an advance rate against estimated case value) and the firm draws against it for payroll, rent, technology, and ongoing case prosecution costs.
Esquire Bank and Counsel Financial are the two most active providers of bank-style inventory lines for plaintiff firms. Their facilities typically come with covenants on case count, qualification milestones, MDL status, and minimum financial ratios. Reporting is heavy, and the lender will want quarterly (sometimes monthly) updates on the case portfolio.
Clean books matter here. Lenders won't underwrite an inventory line off a messy QuickBooks file. We've helped firms close on facilities by getting their bookkeeping for law firms into shape first. The firms that come in with audit-ready financials and a clean case-by-case ledger get faster decisions and better pricing.
Who Are the Major Mass Tort Lenders and Funders?
The market splits into two groups: bank-style attorney lenders and specialty litigation funds.
Bank-style attorney lenders include Esquire Bank, Counsel Financial, Advocate Capital, California Attorney Lending, and RD Legal. These are the firms that build inventory-backed working capital lines and case cost lines. Pricing is closer to commercial bank pricing (think prime-plus or SOFR-plus a spread) and the structure is recourse. They want financial covenants and personal guarantees.
Specialty litigation funds include Burford Capital, Mighty Group, Virage Capital, Centerbridge, Therium, Curiam Capital, and Parabellum Capital. These funds are more likely to take non-recourse positions against specific case portfolios. Pricing is structured as a multiple of capital deployed plus a percentage of proceeds. The headline number is higher, but the firm carries less default risk if the cases lose.
The market has real depth. Westfleet Advisors reported $2.3 billion in new US commercial litigation finance commitments in 2024, with average single-matter deals around $6.6 million and portfolio deals at $16.5 million. After two years of contraction, new commitments rebounded by 23% in 2025, a sign that funder appetite is coming back. A meaningful share of that capital flows into mass tort.
What Does Mass Tort Financing Cost?
The price of mass tort financing depends on which product you're using and which lender. Bank-style facilities typically price at SOFR or prime plus a spread (often several hundred basis points) with origination fees and unused-line fees layered on top. Specialty funds price as a multiple of capital, frequently 1.5x to 3x deployed capital, plus a percentage of proceeds.
The headline rate is rarely the whole cost. Bank facilities can stack fees that double the effective rate when usage is intermittent. Specialty fund deals can carry payment-in-kind interest that compounds inside the facility, so the multiple paid back at exit is meaningfully higher than the multiple quoted at signing. Read every term sheet with a calculator, not a highlighter.
The economic difference between recourse and non-recourse capital matters more than the headline rate. Non-recourse capital is more expensive on paper, but if the cases underperform, the firm survives. Recourse capital is cheaper on paper, but the firm carries the loss. The right answer depends on the firm's balance sheet, the docket's risk profile, and the partners' tolerance for personal exposure.
Tax, Trust Accounting, and Cash Flow Implications
Three areas trip firms up.
Tax. Interest on advanced client costs follows a different rule than interest on firm-level operating debt. Under the Boccardo line of cases, advanced client costs in a contingency case are treated as loans to the client, and interest tied to those costs may be capitalized to the case rather than deducted currently. Firm-level operating interest is generally deductible as ordinary business interest. The split matters. Talk to your tax advisor before assuming.
Trust accounting. Settlement disbursements have to flow through the firm's IOLTA before any lien holder, lender, or referring firm gets paid. ABA Model Rule 1.15 and the equivalent state rules govern the order of disbursement. If a lender's payment instructions conflict with state ethics rules, the ethics rule wins. Firms with sloppy IOLTA trust accounting get into real trouble at settlement.
Cash flow. The single most common mistake we see is firms borrowing aggressively into a mass tort buildup without a weekly cash forecast that models the trough. The trough is the period (usually 18 to 36 months) when the firm has spent on intake and marketing, is paying carrying costs on the financing, but has not yet seen meaningful settlement proceeds. Firms that don't model the trough run out of operating cash before the cases pay.
How Should a Firm Decide Whether to Borrow for a Mass Tort Push?
Three questions, in order.
One: what's your blended case acquisition cost per qualified claimant? Not per intake. Per qualified, paid claimant. That number sets the floor on what each case has to be worth to break even.
Two: what's your modeled settlement value net of fees, liens, co-counsel splits, and financing costs? If the modeled net per case is too thin, the campaign doesn't work, no matter how cheap the financing is.
Three: can the firm survive an extra 18 months of MDL or trial delay? Bellwether trials slip. Global settlement timelines slip. Firms that model the base case but skip the downside case end up renegotiating from a position of weakness.
When we work with plaintiff firms on a financing decision, we start with the KPIs we track for the firm, layer on the campaign-specific math, and pressure-test the cash flow under three scenarios (base, downside, worst). If the firm can't survive the downside case, the answer is to scale the campaign down, not to borrow more.
Bottom Line
Mass tort financing is one of the most powerful tools in plaintiff firm finance. It's also one of the most dangerous.
Three takeaways:
- Mass tort financing isn't one product. It's three: case acquisition, marketing, and working capital. Each has different lenders, pricing, and risk.
- The math runs on cost-per-claimant and modeled settlement timing. Get those wrong and no rate makes the deal work.
- The cash flow trough is what kills firms, not the interest rate. Model the trough before you sign.
Before you commit to a mass tort financing facility, get a fractional CFO or controller who understands plaintiff firm economics to review the term sheet, the cash flow model, and the campaign assumptions. We do this work for plaintiff firms every week. Schedule a consultation and let's pressure-test your numbers before you sign.
Frequently Asked Questions
What is mass tort financing?
Mass tort financing is specialty capital plaintiff law firms use to fund case acquisition, marketing, and operating costs during the multi-year wait between client signup and settlement in mass tort or MDL dockets. It comes in three main forms: case acquisition financing, marketing capital, and working capital lines secured by case inventory. Pricing and structure vary by product and lender.
How is mass tort financing different from litigation finance?
Litigation finance is the broader category of third-party, non-recourse capital provided against expected litigation proceeds, including commercial cases, patent matters, and international arbitration. Mass tort financing is a specialized sub-category built for plaintiff firms running large MDL or coordinated state court inventories, where the capital funds case acquisition and ongoing operations rather than a single commercial dispute.
How much does it cost to acquire a mass tort claimant?
Cost-per-acquired claimant in mass tort campaigns ranges widely, from under a few hundred dollars to several thousand dollars depending on the docket, the channel, and the level of competition for leads. Firms should track blended cost per qualified claimant (after attrition), not just cost per intake, when modeling the economics of a campaign.
Who are the biggest mass tort lenders?
The most active bank-style attorney lenders include Esquire Bank, Counsel Financial, Advocate Capital, California Attorney Lending, and RD Legal. The most active specialty litigation funds include Burford Capital, Mighty Group, Virage Capital, Centerbridge, Therium, Curiam Capital, and Parabellum Capital. Bank lenders typically use recourse facilities; specialty funds typically use non-recourse structures with multiple-of-capital pricing.
Does mass tort financing affect IOLTA or trust accounting?
Yes. Settlement proceeds in plaintiff cases have to flow through the firm's IOLTA trust account before any lender, lien holder, or co-counsel gets paid. ABA Model Rule 1.15 and the equivalent state ethics rules govern the order of disbursement. If a lender's payment instructions conflict with state trust accounting rules, the ethics rule controls. Firms with weak trust accounting get into real trouble at settlement.
